3RP-AYA Intervention in Reducing Stress and Promoting Stress Management in Adolescent and Young Adult Cancer Survivors
- Diagnosed with any cancer between ages 14 and 29
- Completed cancer treatment within the past 5 years
- Unwilling or unable to participate in the study
- Unable to speak or read English
- Is medically or otherwise unable to participate (as determined by a physician or study principal investigator [PI])
- Unwilling or unable to participate in study sessions delivered via the Partners Telehealth videoconferencing software
- Participation in a focus group during phase 1 (DF/HCC 17-315) or the sister-protocol (DF/HCC 17-063)
I. To examine, in a pilot randomized controlled trial (RCT) (total n=72, goal of having approximately n=60 completers), the feasibility and acceptability of an 8-session stress-management and resiliency group program (3RP-AYA) delivered via videoconference technology for survivors of AYA cancer between the ages of 16-29 at study enrollment, but who were diagnosed between ages 14 and 29 and who are within 5 years of treatment completion.
I. Examine the preliminary effects of the 3RP-AYA on stress and stress management among AYAs.
II. Examine the preliminary effects of the 3RP-AYA on psychosocial measures of mindfulness, depressed mood, anxiety and stress collected at three timepoints: T0 (baseline), T1 (immediate start resiliency intervention group [IG]: posttreatment, waitlist control group [WG]: baseline), T2 (IG: 3 month follow-up, WG: posttreatment).
III. Explore the feasibility and acceptability of collecting hair samples to examine intervention-related changes in cortisol, a stress biomarker.
IV. Examine AYA reasons for deciding not to participate in this behavioral trial.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive 3RP-AYA intervention consisting of a group session once weekly over 90 minutes each for 8 weeks.
GROUP II: Patients receive 3RP-AYA intervention consisting of a group session once weekly over 90 minutes each for 8 weeks after 3 months.
After completion of study program, patients are followed up at 3 months.
Trial Phase Phase NA
Trial Type Supportive care
Dana-Farber Harvard Cancer Center
- Primary ID 18-428
- Secondary IDs NCI-2018-03786
- Clinicaltrials.gov ID NCT03768336